MicroRNAs (miRNAs) are a family of endogenous small noncoding RNA molecules, of 19-28 nucleotides in length. In humans, up to 3% of all genes are estimated to encode these evolutionarily conserved sequences. miRNAs are thought to control expression of thousands of target mRNAs. Mammalian miRNAs generally negatively regulate gene expression by repressing translation, possibly through effects on mRNA stability and compartmentalisation, and/or the translation process itself. An extensive range of in silico and experimental techniques have been applied to our understanding of the occurrence and functional relevance of such sequences, and antisense technologies have been successfully used to control miRNA expression in vitro and in vivo. Interestingly, miRNAs have been identified in both normal and pathological conditions, including differentiation and development, metabolism, proliferation, cell death, viral infection and cancer. Of specific relevance and excitement to the area of diabetes research, miRNA regulation has been implicated in insulin secretion from pancreatic b-cells, diabetic heart conditions and nephropathy. Further analyses of miRNAs in vitro and in vivo will, undoubtedly, enable us determine their potential to be exploited as therapeutic targets in diabetes. Following transcription of miRNA genes, one or two miRNAs can be generated from a single hairpin-loop precursor RNA (Ref. 4) , although some precursor molecules are known to contain National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland. *Corresponding author: Lorraine O'Driscoll, National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, Ireland. Tel: +353 1 7005402; Fax: +353 1 7005484; E-mail: lorraine. odriscoll@dcu.ie more than six hairpin loops, referred to as miRNA clusters (Ref. 5) . miRNAs bind to complementary sequences within the 3 0 untranslated region (3 0 UTR) of their target mRNA transcript and, by virtue of proteins associated with the miRNA, usually direct target cleavage (if there is perfect complementarity with the target), or translational repression without cleavage of target (if partial complementarity with target) (Ref. 6 ). The 'seed' region (nucleotides 2-7) at the 5 0 end of the miRNA is often sufficient for specificity and functionality of the miRNA (Ref. 7) .
Hundreds of miRNA genes are predicted to be present in mammals, with each miRNA apparently regulating multiple mRNAs, and multiple miRNAs regulating each mRNA (Refs 8, 9, 10) . miRNAs are proposed to be involved in regulating at least a third of all genes within the human genome (Ref. 11) although, of the hundreds of miRNAs identified to date, the biological function(s) of only very few has been elucidated (Ref. 12 ).
miRNA discovery
ThefirstmiRNA,lin-4,wasidentifiedin1993during a genetic screen for mutants that disrupt developmental timing in Caenorhabditis elegans (Ref. 13 ). The lin-4 gene was shown to produce a pair of small RNAs of approximately 61 and 22 nucleotides in length, with the larger being the precursor of the smaller. Both RNAs contained sequences complementary to sites in the 3 0 UTR of lin-14 mRNA, suggesting that lin-4 regulates lin-14 translation by an antisense RNA-RNA interaction (Refs 14, 15) . A second C. elegans miRNA, let-7, was discovered in 2000 (Ref. 16 ); let-7 is also involved in developmental timing and represses expression of the lin-41 and hbl-1 mRNAs ( Refs 17, 18, 19) . let-7 and lin-41 are phylogenetically conserved among a wide variety of multicellular organisms, indicating that these small RNAs could represent a general mechanism for post-transcriptional regulation (Ref. 4) .
Since these initial discoveries, many miRNAs have been identified in single-celled and multicellular organisms, including plant and mammalian cells (a database of known and predicted endogenous miRNAs is available at http://www.sanger.ac.uk/Software/Rfam/ mirna). Although the exact number of miRNA genes in the human genome has yet to be determined, current estimates range to approximately 800 (http://microrna.sanger.ac. uk/sequences/). It is thought that many new miRNA genes may have evolved through duplication and mutation, with the number of gene duplications possibly correlating with the level of complexity of the organism (Refs 11, 20) . Furthermore, RNA editing (i.e. site-specific modification of an RNA sequence to yield a product differing from that encoded by the DNA template) has been reported in at least 6% of human miRNAs, which may further increase the diversity of miRNAs and their targets (Ref. 21 Translocation of pre-miRNAs across the nuclear envelope to the cytoplasm is facilitated by the nuclear transport protein exportin-5 ( Fig. 1) , which recognises the two-nucleotide 3 0 overhangs on the pre-miRNA hairpin. Upon arrival in the cytoplasm, pre-miRNAs are cleaved by a second double-stranded-RNAspecific RNAse-III-type endonuclease, Dicer (DICER1) (Fig. 1) , which acts in conjunction with a double-stranded-RNA-binding protein partner, transactivation-responsive RNA-binding protein (TRBP/TARBP2P) ( Refs 30, 31, 32) . In human cells, TRBP recruits argonaute protein (Ago2/ EIF2C2); together Dicer, TRBP and Ago2 form the miRNA RISC loading complex (miRLC; RISC stands for 'RNA-induced silencing complex') (Refs 33, 34) . Cleavage of the pre-miRNA by Dicer produces an approximately 22 nucleotide double-stranded miRNA duplex -one strand of Figure 1 . miRNA biogenesis and target mRNA regulation. Primary microRNA (pri-miRNA) generated from transcription in the nucleus is cleaved by Drosha (in conjunction with DGCR8) to generate precursor miRNA (pre-miRNA), which is translocated across the nuclear membrane by the action of exportin 5. In the cytoplasm, pre-miRNA is cleaved by Dicer with cofactor TRBP (transactivation-responsive RNA-binding protein) and argonaute protein (Ago), which together make up the complex miRLC [miRNA RISC (RNAinduced silencing complex) loading complex] to produce a double-stranded miRNA duplex. This is then unwound by the helicase armitage (not shown), releasing single-stranded mature miRNA. Mature miRNA becomes assembled into miRNPs (miRNA-containing ribonucleoprotein particles), which always include an argonaute protein. A number of other proteins may be -but are not always -involved in miRNP function; these include gemin3, gemin4, vasa intronic gene product (VIG), fragile-X-related protein (dFXR), tudor-SN, fragile X mental retardation protein (FMRP) and survival of motor neuron protein (SMN). miRNA guides miRNP to its mRNA target and, depending on the level of complementarity, can initiate cleavage or translational repression of mRNA target (see Fig. 2 ). The Ago2-bound mature miRNA then becomes assembled into effector complexes termed miRNAcontaining ribonucleoprotein particles (miRNPs) (Ref. 37) (Fig. 1) . Several forms of miRNPs exist that differ in size and composition, but each form of miRNP contains a member of the argonaute protein family. The major function of miRNAs is to guide the miRNP complex to its target mRNA, where its associated argonaute protein mediates the effect (Ref. 38) . Several other miRNP components have been identified, including gemin3 (DDX20), gemin4, vasa intronic gene product (VIG), fragile-X-related protein (dFXR), and the tudor staphylococcal-nucleasedomain-containing protein (tudor-SN) (Refs 39, 40). Gemin3 is a putative DEAD-box RNA helicase, which may function in the unwinding of the mRNA target (Ref. 35) , but the precise role of the other proteins in RNA-silencing events remains unclear. Although miRNAs function primarily in the cytoplasm, one miRNA, mir-29b has been found to localise in the nucleus; this is likely due to a hexanucleotide terminal motif in the 3 0 region that directs the mature miRNA to be imported back into the nucleus after it is processed in the cytoplasm (Ref. 41 ).
Mechanism(s) of miRNA action
In mammals, miRNAs usually exhibit partial complementarity with their mRNA targets; perfect or near-perfect base pairing is quite rare in these organisms, but is predominantly found in plant miRNAs. Partial complementarity of miRNA to mRNA usually leads to translational inhibition (Ref. 42) , although animal miRNAs can also induce target degradation despite the lack of perfect complementarity (Refs 43, 44, 45) . Several proposed models exist for the mechanism of translational repression, including miRNAs repressing translation at both pre-initiation and post-initiation stages (Fig. 2) , and effects on mRNA stability (decapping and deadenylation) and compartmentalisation into translationally repressive sites (Fig. 2) ; it still remains to be deciphered which of these model mechanisms are cause and consequence of translational repression. miRNAs affecting initiation steps only affect capdependent translation, possibly through m 7 G cap recognition (Refs 46, 47, 48, 49, 50) . Argonaute proteins contain structural similarities to the cap-binding protein eIF4E, and thus it has been suggested that translational repression may occur due to competition between argonaute and eIF4E for binding to the cap structure (Ref. 51) (Fig. 2a) . Argonaute proteins are also thought to recruit eIF6, which binds to the large ribosomal subunit, preventing binding of the small subunit and thus inhibiting mRNA translation (Ref. 52) (Fig. 2a) .
Much evidence also exists for post-initiation mechanisms of repression, which affect both cap-dependent and cap-independent translation (Ref. 53) . Polysome profile experiments indicate that, under conditions of translational repression, target mRNAs are fully loaded with ribosomes (Refs 15, 54), a number of which are engaged in active translation (Ref. 53) , suggesting that translation initiation and elongation phases are not compromised. Two possible theories were suggested to explain these findings. The ribosome 'drop-off' theory suggests that ribosomes engaged in translation of miRNA-associated mRNAs are prone to terminate translation prematurely (Fig. 2b) . Alternatively, association of active ribosomes with repressed mRNAs could also be explained by the ability of miRNP complex to recruit proteolytic enzymes to degrade the nascent polypeptide as it emerges from the ribosome (Ref. 15) (Fig. 2b) . Conflicting evidence exists on the role of proteolytic enzymes in miRNA function, as targeting of reporter proteins and the use of proteinase inhibitors have shown no effect on translational repression (Refs 50, 53).
miRNAs are apparently also involved in regulating mRNA stability and induction of decay of repressed mRNA targets. Argonaute proteins, miRNAs and their repressed target mRNAs have recently been shown to be compartmentalised in cytoplasmic foci called P-bodies (Refs 50, 55, 56, 57, 58, 59) . These are sites of translational repression and mRNA decay; they are rich in factors associated with these processes, and are lacking in ribosomes or any other factors associated with translation initiation (Ref. 60) . It is proposed that P-body proteins may participate in the formation of a repressive complex on the target mRNA, which could eventually lead to mRNA aggregation into P-bodies (Ref. 61) . Within P-bodies, miRNA/ mRNA-bound argonaute protein recruits GW182 protein (TNRC6A), which subsequently recruits deadenylating enzyme CCR4-NOT1 (CNOT1), and this is followed by mRNA decapping by DCP1-DCP2 enzyme -thereby affecting stability of repressed mRNA. 7 G-cap-dependent translation through competition of the argonaute protein with the eIF4G initiation complex for binding to the cap structure; argonaute proteins also recruit eIF6, which prevents large ribosomal subunit binding to the small subunit. (b) At postinitiation stages, miRNPs may cause ribosomes to terminate translation prematurely, generating truncated polypeptides, or recruit proteolytic enzymes that degrade the polypeptide chain as it emerges from the ribosome. Repressed mRNAs arising from these models can then be transported to P-bodies for storage or degradation: the miRNP complex recruits GW182 protein; the latter subsequently recruits deadenylase enzyme CCR4 -NOT1; the mRNA is then decapped by DCP1 -DCP2, and degraded by exonuclease activity of XRN1. miRNAs represent an efficient mechanism for viruses to use to manipulate host machinery, as they require less space on the viral genome than alternative protein products. Viral miRNAs can target both viral and host mRNAs for repression. Twelve miRNAs from the Karposi sarcoma-associated herpesvirus (KSHV) genome expressed in cells led to the downregulation of a number of genes including thrombospondin 1 (THBS-1), which is a known tumour suppressor and antiangiogenic factor. It is thought that these KSHV miRNAs may contribute directly to pathogenesis of KSHV by expert reviews 
miRNAs associated with b-cell insulin secretion
Recent experimental work has revealed a limited number of miRNAs -including mir-375, mir124a and mir-9 -associated with various subcellular events involved in glucose-stimulated insulin secretion (GSIS) (Refs 126, 127, 128 ). In addition, bioinformatic analysis has indicated potential miRNA target sites in a range of other mRNAs encoding proteins involved in exocytosis -including VAMP2 (vesicle-associated membrane protein 2), SNAP25 (synaptosomalassociated protein 25kDa), syntaxin-1, Rab27a 
mir-375
Selective cloning of small RNAs 21-23 nucleotides in length from the b-cell line MIN-6 and the a-cell line TC1 led to the identification of mir-375, a miRNA specific to pancreatic islet cells. Gainand loss-of-function experiments on mir-375 indicated it was involved in GSIS in b-cells, with overexpression resulting in reduced GSIS and, conversely, knockout of expression resulting in enhanced GSIS (Ref. 105 ). mir-375 apparently acts on the later stages of exocytosis to reduce insulin secretion.
Based on sequence information, myotrophin has been confirmed as a target of mir-375 action (Table 1) (Fig. 3a) . Myotrophin also acts in the nucleus as a transcription factor to activate nuclear factor kB (NF-kB), a critical component in maintaining GSIS in b-cells (Refs 134, 135) (Fig. 3a) . 
mir-124a
Mir-124a exists in three different isoforms -mir124a1, 2 and 3 -encoded on chromosome 14, 3 and 2, respectively, in the mouse genome. The isoform mir-124a2 is differentially expressed during pancreas development, with a sixfold upregulation at embryonic stage e18.5 compared with e14. 5 (Fig. 3b) .
FOXA2 is an upstream regulator of the homeobox protein PDX-1 (Refs 141, 142) . PDX-1 is essential for b-cell differentiation, glucose homeostasis and pancreas development (Refs 143, 144) (Fig. 3b) , and the human orthologue (insulin promoter factor; IPF1) is mutated in a proportion of early-onset type 2 diabetic patients (Ref. regulates expression of the insulin gene; consequently, overexpression and inhibition of mir-124a2 leads to a decrease and increase in insulin mRNA levels, respectively (Ref. 
mir-9
Mir-9 is expressed predominately in neurons in both human and mouse models (Refs 150, 151), and to a lesser extent in pancreatic b-cells in rat and mouse models (Ref. 152). Onecut2 transcription factor (OC2), which negatively regulates granuphilin (also known as SLP4/ SYTL4) expression, has been identified as a mir-9 target (Table 1) . A basal level of mir-9 expression is needed to maintain optimum onecut2 expression levels for normal b-cell function (Ref. 152 ), but mir-9 overexpression in rat INS-1E b-cells leads to a reduced GSIS in these cells (Ref. 152) .
Granuphilin associates with insulin secretory granules (Ref. 153 ) and promotes targeting of these granules to the plasma membrane (Ref. 154) ; however, it is a negative modulator of exocytosis as it imposes a constraint to inhibit fusion until the correct signals are received by the cell (Ref. 154) . Overexpression of mir-9 leads to increased levels of granuphilin expression due to the removal of the repressive effects of onecut2 on the granuphilin promoter (Ref. 152) , and hence reduced GSIS is observed as a result of its negative effects on exocytosis. Granuphilin-null mice also show impaired GSIS, with reduced quantity of insulin granules docked to the b-cell membrane, and conversely exhibit increased insulin exocytosis in response to stimulus (Ref. 155) .
Binding partners of granuphilin include the GTP-binding proteins Rab3/Rab27, the SNAREbinding protein Munc-18 and the tSNARE protein syntaxin-1, which are involved in exocytosis of secretory granules in pancreatic b-cells (Refs 152, 156, 157 ). mir-9-induced reduction of exocytosis does not occur through manipulation of Rab3, Rab27 and SNARE proteins such as SNAP25, VAMP-2 and syntaxin-1, as the expression levels of these key exocytosis proteins are unchanged in mir-9-transfected cells relative to control cells (Ref. 152) . However, it is as yet unknown whether the mir-9-mediated reduction of secretagoguestimulated exocytosis via granuphilin occurs figure. ) (a) Possible microRNA (miRNA) inhibition of insulin secretion via myotrophin. Overexpression of the myotrophintargeting miRNA mir-375 results in reduced glucose-stimulated insulin secretion, which can be explained through cytoplasmic and/or nuclear actions of myotrophin. Myotrophin interacts with capping protein to inhibit actin polymerisation. Inhibition of actin polymerisation allows access of insulin granules to the cell membrane for exocytosis. In addition, myotrophin interacts with transcription factor NF-kB, which controls expression of several genes critical for glucose-stimulated insulin secretion. Myotrophin also contains putative binding sites for the miRNAs let-7b and mir-124a. (b) Possible mir-124a involvement in glucose homeostasis. Mir-124a targets Rab27a and also FOXA2 (directly and indirectly via CREB1). Myotrophin has also been identified as a potential mir-124a target. FOXA2 may influence several targets relevant to diabetes via PDX-1, including insulin mRNA levels and possibly also K ATP channel subunits KIR6.2 and SUR1 (involved in regulated insulin release). It also plays a role in b-cell differentiation, pancreas development and glucose homeostasis. Using a luciferase reporter system, SIP1 was validated as a target of mir-192 regulation (Table 1) mir-192 overexpression leads to repression of translation of its target SIP1, thereby increasing levels of collagen expression. Repression of dEF1 using short hairpin RNA (shRNA; for stable transfection of siRNA) shows similar effects, resulting in increased levels of collagen expression; however, double transfection of a mir-192 mimic and dEF1 shRNA shows a much larger increase in collagen expression than either achieved separately, suggesting that these two mechanisms act synergistically in the control of collagen expression (Ref. 166) .
In vivo analysis of type 1 and type 2 diabetic mice showed elevated levels of mir-192, TGF-b and collagen 1a2 in the renal glomeruli (Ref. 166) , suggesting the possible involvement of mir-192-mediated collagen expression in the pathogenesis of diabetic nephropathy, or other diabetic complications where TGF-b levels are raised.
miRNAs associated with diabetic heart
Cardiovascular disease is the principal cause of death in more than 60% of diabetic cases, with an annual mortality of approximately 5.4%, thereby decreasing life expectancy by up to 10 years (Refs 169, 170). For diabetic patients, the most prominent cardiac electrical disturbance is an abnormal QT interval, which is associated with increased risk of sudden cardiac death (Refs 171, 172) . QT interval is the total duration for ventricular depolarisation and repolarisation of cardiac myocytes, which is controlled by the flow of inward and outward ion currents. Increasing inward currents and/or decreasing outward currents lead to prolonged QT interval. The outward currents occur via a number of K þ channels.
Human ether-a-go-go related gene (HERG) encodes one of these channels -the rapid delayed rectifier K þ current channel (I Kr ). HERG is downregulated in diabetic hearts, thereby contributing to slowed repolarisation and prolonged QT interval (Refs 173, 174) . HERG expression is downregulated at the posttranscriptional level: HERG mRNA levels remain constant, while HERG protein levels are reduced by 60% in diabetic heart as compared with nondiabetic/control heart (Refs 173, 174, 175).
mir-1 and mir-133 are specifically expressed in adult cardiac and skeletal muscle tissues, and upregulated in rabbit diabetic heart tissue and also in ventricular samples from human diabetic patients (Refs 104, 176) . Using a luciferase reporter plasmid and western blotting, HERG mRNA was shown to be a target of mir-133 action (Table 1) , while mir-1 had no effect on HERG expression (Ref. 175 
Clinical implications/applications
Until recently, miRNAs had not been considered as classical therapeutic targets, as they do not code for proteins. Initial studies aimed at exploiting miRNAs as a form of therapy have shown promising results. Following intravenous injection of modified antisense oligonucleotides (termed antagomirs) into mice, in vivo inhibition of four miRNAs -mir-16, mir-122, mir-192 and mir-194 -has been successfully demonstrated (Ref. 96) . This approach resulted not only in blockage of target miRNAs, but also in their degradation in most organs analysed, including liver, kidney, heart, lung, intestine, bone marrow, muscle, skin, fat, ovaries and adrenals. Lack of effect observed in brain is possibly due to restricted diffusion of charged nucleic acids across the blood-brain barrier. Alternative approaches to targeting miRNAs therapeutically by inhibiting Drosha, Dicer or other miRNA pathway components are being investigated. Conversely, where reduced miRNA expressed is associated with a disease phenotype and increased expression of relevant miRNA could be of potential therapeutic relevance to rescue disease phenotype, introduction of miRNA mimics is being investigated. However, suitable expression vectors have yet to be identified for the safe delivery and maintenance of such effects long-term (Ref. 178 ).
Research in progress and outstanding research questions
The importance of miRNAs in normal and pathological conditions is still being realised. Recent studies have clearly indicated an association between dysregulated expression of these short RNAs in regulated and defective insulin secretion from b-cells and in diabetic kidney and heart disease.
Recently, overexpression of a specific miRNA (mir-29) -which is upregulated in diabetic rats -has been found to have a functional role in insulin resistance (Ref. 179) and, furthermore, analysis of murine pancreas development has indicated a unique miRNA profile to be necessary during pancreas development for generation of normal b-cells (Ref. 180) . So, while studies associating miRNAs with diabetes are so far limited in numbers, they suggest important roles for miRNAs as potential biomarkers and possibly therapeutic targets. More extensive studies investigating the expression and functional relevance of miRNAs in both type 1 and type 2 diabetes will undoubtedly increase our understanding of these complex conditions and will hopefully aid in the identification of novel therapeutic targets and interventions. Features associated with this article Figures  Figure 1 . miRNA biogenesis and target mRNA regulation. Figure 2 . Proposed mechanisms of miRNA action. Figure 3 . Co-ordinated regulation of insulin exocytosis by miRNAs. Table  Table 1 . miRNAs implicated in b-cell insulin secretion and diabetic complications, and their mRNA targets. 
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